Blockage of IL-23/IL-17 axis (such as, anti-IL-12/IL-23, or anti-IL-23) may be potential therapy for ICI-pneumonitis, especially steroid-refractory ICI-pneumonitis. This evidence concerns the gene IL23A and pneumonitis.